Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

NCT03660826 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

288

Enrollment

NIH

Sponsor class

Conditions

Endometrial Adenocarcinoma
Endometrial Mixed Cell Adenocarcinoma
Endometrial Serous Adenocarcinoma
Endometrial Undifferentiated Carcinoma
Endometrioid Adenocarcinoma
Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspirate
PROCEDURE: Bone Marrow Biopsy
DRUG: Capivasertib
DRUG: Cediranib Maleate
PROCEDURE: Computed Tomography
BIOLOGICAL: Durvalumab
PROCEDURE: Echocardiography Test
PROCEDURE: Multigated Acquisition Scan
DRUG: Olaparib

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]